Influence of UDP-Glucuronosyltransferase Polymorphisms on Mycophenolate Mofetil-Induced Side Effects in Kidney Transplant Patients

Transplantation Proceedings

Volumn 40, Issue 3, 2008, Pages 708-710

  Betonico G N ^a   Abbud Filho, M ^a   Goloni Bertollo, E M ^a   Alvarenga, M P S ^a   Guillemette, C ^b   Villeneuve, L ^b   Benoit Biancamano, M O ^b   Pavarino Bertelli, E C ^a  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b Université Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD DISEASE; BRAZIL; CONTROLLED STUDY; DIARRHEA; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

CODON; DIARRHEA; GLUCURONOSYLTRANSFERASE; HEMATOLOGIC DISEASES; HUMANS; INFECTION; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES;

EID: 43049148025     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.03.007     Document Type: Article

References (7)

1. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46 (2007) 13
2. Picard N., Ratanasavanah D., Prémaud A., et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33 (2005) 139
3. Bernard O., and Gillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occuring variants. Drug Metab Dispos 32 (2004) 775
4. Levesque E., Delage R., Benoit-Biancamano M.O., et al. The impact of UGT1A8, UGT1A9 and UGT2B7 genetic polymorphism on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 81 (2007) 392
5. van Gelder T., and Shaw L.M. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80 (2005) S244
6. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13 (2002) 759
7. Kagaya H., Inoue K., Miura M., et al. Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol 63 (2007) 279